CBD and Dravet Syndrome
Pharmaceutical-grade cannabidiol is one of the few cannabis-derived treatments with strong randomized trial evidence for a specific condition.
This is the rare cannabis story where the science is solid. Purified pharmaceutical CBD (Epidiolex/Epidyolex) reduces convulsive seizures in Dravet syndrome in multiple randomized controlled trials, and it's FDA- and EMA-approved for that use. That does not mean any CBD oil from a dispensary or wellness shop will do the same — purity, dose, and drug interactions matter enormously. It also doesn't mean CBD cures Dravet. Most patients still have seizures, and side effects are real.
Plain-language summary
Dravet syndrome is a severe genetic epilepsy that starts in infancy, usually caused by mutations in the SCN1A gene. Seizures are frequent, often triggered by fever, and standard antiseizure drugs frequently fail [1].
Cannabidiol (CBD) is a non-intoxicating compound from cannabis. A purified pharmaceutical version — sold as Epidiolex in the US and Epidyolex in Europe — has been tested in randomized, placebo-controlled trials in children with Dravet syndrome. In those trials, CBD roughly cut convulsive seizure frequency in half on average, compared to about a 13–27% reduction with placebo [2][3]. The FDA approved it for Dravet in 2018 [4].
This article is about that specific drug, at studied doses, in this specific condition. It is not medical advice. Dravet syndrome is life-threatening and treatment decisions belong with a pediatric epileptologist.
What probably works (strong evidence)
Pharmaceutical CBD reduces convulsive seizure frequency in Dravet syndrome. Strong evidence
The pivotal trial (Devinsky et al., NEJM 2017) randomized 120 children and young adults with drug-resistant Dravet to CBD 20 mg/kg/day or placebo on top of existing antiseizure drugs. Median convulsive seizure frequency dropped from 12.4 to 5.9 per month on CBD, versus 14.9 to 14.1 on placebo. 43% of CBD patients had ≥50% seizure reduction, versus 27% on placebo [2].
A second trial (Miller et al., 2020) compared 10 mg/kg/day and 20 mg/kg/day to placebo and confirmed efficacy at both doses, with the lower dose better tolerated [3].
On the basis of these trials, CBD is approved by the FDA [4] and EMA for seizures associated with Dravet syndrome. Long-term open-label extension data suggest the effect persists for at least 1–2 years in responders [5].
What might work (weak or preliminary evidence)
Non-convulsive seizure reduction. Trials primarily measured convulsive seizures. Effects on other seizure types in Dravet are less well characterized. Weak / limited
Quality of life and caregiver-reported global improvement. Caregiver Global Impression of Change scores improved more on CBD than placebo in pivotal trials [2][3], but these are subjective and unblinding from side effects (e.g. somnolence) is a real concern. Weak / limited
Artisanal / full-spectrum CBD products. Observational and survey studies (e.g. Press et al., 2015; Porter & Jacobson, 2013) reported seizure reduction with non-pharmaceutical CBD-rich extracts [6][7]. These studies lack blinding, have selection bias, and product contents were often unverified. They generated the hypothesis that pharma trials later confirmed — but they don't tell you that a given dispensary oil works. Weak / limited
What doesn't work or has no good evidence
Seizure freedom. Complete seizure freedom on CBD is uncommon in Dravet. Most responders still have seizures, just fewer [2][3]. Strong evidence (for the negative claim)
Cognitive or developmental improvement independent of seizure control. No high-quality trial has shown that CBD improves the cognitive trajectory of Dravet syndrome. No data
Reduction in mortality or SUDEP. Dravet carries elevated risk of sudden unexpected death in epilepsy. No trial has been powered to show CBD reduces this. No data
Equivalence of dispensary/wellness CBD oils to Epidiolex. Independent testing has repeatedly found over-the-counter CBD products mislabeled for content, sometimes containing significant THC, and not standardized to the doses used in trials [8]. There is no evidence these are equivalent to the pharmaceutical product. No data
'Entourage effect' claims that whole-plant extracts outperform purified CBD in Dravet specifically — popular online — are not supported by controlled human trials in this condition. Disputed
What we don't know
- Whether CBD's benefit is partly mediated by raising blood levels of clobazam's active metabolite N-desmethylclobazam, rather than by CBD itself. Subgroup analyses suggest CBD works in patients not on clobazam, but the interaction is real [9].
- The optimal long-term dose, and whether tolerance develops over years.
- Whether early CBD initiation changes long-term outcomes (cognition, mortality) versus only seizure counts.
- How CBD compares head-to-head with newer Dravet-specific drugs like fenfluramine and stiripentol.
- Whether any non-pharmaceutical CBD product can reliably reproduce trial results.
Comparison with standard treatments
First-line treatments for Dravet syndrome typically include valproate and clobazam. Stiripentol (added to valproate + clobazam) and fenfluramine are also approved Dravet-specific therapies [1][10].
In the absence of head-to-head trials, indirect comparisons suggest fenfluramine may produce larger reductions in convulsive seizure frequency than CBD, though with a different side-effect profile (appetite suppression, cardiac monitoring required) [10]. CBD, stiripentol, and fenfluramine are typically considered as add-ons, not replacements for baseline therapy.
Sodium-channel blockers like carbamazepine, lamotrigine, and phenytoin can worsen seizures in Dravet and are generally avoided [1].
CBD's main practical advantage is a relatively favorable side-effect profile and lack of intoxication. Its main disadvantages are drug interactions (especially clobazam, valproate) and cost.
Risks and side effects
Common adverse events in CBD trials for Dravet [2][3][5]:
- Somnolence / sedation (often worse with concurrent clobazam)
- Decreased appetite
- Diarrhea
- Elevated liver transaminases, particularly when co-administered with valproate. Liver function monitoring is recommended.
- Drug interactions: CBD inhibits CYP2C19 and CYP3A4, raising levels of clobazam's active metabolite and potentially other drugs [9].
Serious adverse events occurred in roughly 16–25% of CBD-treated patients in trials, often related to liver enzyme elevations or status epilepticus [2][3]. Withdrawal due to adverse events was more common on CBD than placebo.
For non-pharmaceutical CBD products there are additional risks: inaccurate labeling, contamination with pesticides or solvents, and unintended THC exposure in children [8].
Not medical advice
This article is not medical advice. Dravet syndrome is a serious, life-threatening condition. Do not start, stop, or change any antiseizure medication — including CBD — without working directly with a qualified neurologist or epileptologist. Drug interactions and liver effects make unsupervised use of CBD alongside other antiseizure drugs genuinely dangerous. If you are a caregiver considering CBD for a child with Dravet, ask your specialist about pharmaceutical-grade cannabidiol specifically, not generic wellness products.
Sources
- Peer-reviewed Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761-1777.
- Peer-reviewed Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376(21):2011-2020.
- Peer-reviewed Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurology. 2020;77(5):613-621.
- Government U.S. Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. June 25, 2018. ↗
- Peer-reviewed Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019;60(2):294-302.
- Peer-reviewed Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy & Behavior. 2015;45:49-52.
- Peer-reviewed Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior. 2013;29(3):574-577.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708-1709.
- Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-1251.
- Peer-reviewed Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243-2254.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- CBD and Lennox-Gastaut Syndrome — Pharmaceutical-grade cannabidiol reduces drop seizures in Lennox-Gastaut syndrome, with st...